This informal CPD article ‘Contamination Control Strategies: More Than Just Annex 1’, was provided by Pharmalliance Consulting, who offer specialist support to pharmaceutical companies to maintain and increase quality compliance levels.
When the EU released its revised Annex 1, the focus naturally fell on sterile manufacturing. The new expectations were extensive, particularly around cleanroom design, aseptic processing, and contamination control (1). Yet one important point is often overlooked: contamination control is not limited to sterile products.
The principles of a Contamination Control Strategy (CCS) extend well beyond the cleanroom. Across sectors, from 503B outsourcing facilities to oral solid dose (OSD) manufacturing, regulators are increasingly aligned in their expectations that contamination control must be structured, proactive, and demonstrable (2,3).
Why CCS Thinking is Expanding
Historically, non-sterile facilities often assumed they were at lower risk. OSD plants produce tablets and capsules, and other sectors may deal with products not intended for sterile administration. However, regulatory enforcement trends indicate a shift in expectations.
Recent regulatory observations highlight recurring issues:
- 503B outsourcing facilities continue to receive citations for insanitary conditions, inadequate aseptic practices, and insufficient environmental monitoring programmes (4,5).
- OSD manufacturers are cited for cross-contamination risks, ineffective cleaning validation, and poor segregation of potent compounds (6,9).
- More broadly, regulators expect facilities to demonstrate that contamination risks are understood, controlled, and supported by a robust quality system (2,3).
The direction is clear: contamination control must be addressed holistically, regardless of product type.
Common CCS Elements Across All Sectors
The core components of a CCS are highly transferable across industries. Whether manufacturing sterile injectables or non-sterile products, the same foundational principles apply.
- Facility and flow design. Effective layouts, including segregation of materials and personnel, are critical to preventing cross-contamination and mix-ups (6,9).
- Environmental and utility monitoring. While Annex 1 emphasises environmental monitoring, non-sterile facilities must also control critical utilities such as water, compressed air, and HVAC systems to prevent contamination risks (1,7).
- Personnel practices. Personnel remain the primary contamination vector. Training, hygiene, and adherence to procedures are essential across all facility types (3,7).
- Cleaning and disinfection. Cleaning must be treated as a validated lifecycle activity, ensuring consistent removal of residues and contaminants (6,7).
- Raw material and supplier controls. Raw materials represent a significant contamination risk and require qualification, testing, and appropriate controls (3,7).
- Quality oversight and risk management. A CCS must be embedded within a pharmaceutical quality system, with risks identified, assessed, and mitigated using structured approaches such as Quality Risk Management (2,3).
From Document to Mindset
A common pitfall is treating the CCS as a static document prepared for inspection purposes. In practice, regulators expect a lifecycle approach, where control strategies are maintained, reviewed, and improved over time (2,3).
A CCS should evolve alongside changes in products, processes, equipment, and monitoring data. It should also be reflected in organisational culture. Personnel must understand not just what procedures to follow, but why they are critical to contamination control.
Quality culture plays a decisive role. Regulatory guidance and industry best practice consistently highlight that contamination control failures are often linked not only to technical gaps, but to weaknesses in oversight, accountability, and decision-making (5,8).
Why CCS Benefits Every Facility
Implementing CCS principles delivers benefits beyond regulatory compliance:
- Protecting patients and consumers. Effective contamination control reduces the risk of harm associated with microbial, particulate, or cross-contamination events (1,7).
- Driving consistency. Structured approaches ensure processes are repeatable and less dependent on individual practices (2).
- Building trust. Facilities that can clearly demonstrate how contamination risks are controlled are better positioned with regulators, customers, and partners.
Conclusion
Annex 1 may have brought CCS into sharper focus, but its relevance extends across all manufacturing sectors. Both sterile and non-sterile facilities are expected to demonstrate proactive and integrated contamination control strategies.
For outsourcing facilities, OSD manufacturers, and other regulated industries, the message is consistent: contamination control is not a standalone activity or a one-time exercise. It is a comprehensive strategy embedded within operations and sustained through quality culture and continuous improvement.
The influence of Annex 1 reflects a broader regulatory shift. The question is no longer whether a facility needs a CCS, but how robust, integrated, and effective that strategy truly is.
We hope this article was helpful. For more information from Pharmalliance Consulting, please visit their CPD Member Directory page. Alternatively, you can go to CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.
References
(1) The European Commission, 2022. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products, Brussels, Belgium.
(2) International Council for Harmonisation, 2025. ICH Q9(R1) – Quality Risk Management, Step 5 (Revision 2), Geneva, Switzerland.
(3) International Council for Harmonisation, 2008. ICH Q10 – Pharmaceutical Quality System, Geneva, Switzerland.
(4) U.S. Food and Drug Administration, 2020. Current Good Manufacturing Practice – Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FDCC Act (Revised Draft Guidance for Industry), Silver Spring, MD, United States of America.
(5) U.S. Food and Drug Administration, 2020. Insanitary Conditions at Compounding Facilities (Guidance for Industry), Silver Spring, MD, United States of America.
(6) U.S. Government Publishing Office, n.d. 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals, United States of America.
(7) World Health Organization, 2011. WHO Technical Report Series No. 961, Annex 6: WHO Good Manufacturing Practices for Sterile Pharmaceutical Products, Geneva, Switzerland.
(8) Parenteral Drug Association (PDA), 2014. Technical Report No. 90: Contamination Control Strategy, Bethesda, MD, United States of America.
(9) Pharmaceutical Inspection Co-operation Scheme, 2018. PI 043-1 Aide-Memoire –
Cross-Contamination in Shared Facilities, Geneva, Switzerland.
